MicroPort® Attends CBS2016

Nanjing, China – From December 1 to December 4, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended the 9th Left Main & Coronary Bifurcation Summit ("CBS 2016") held in Nanjing of Jiangsu Province. The CBS 2016 was hosted by Nanjing Heart Center, Nanjing First Hospital, Nanjing Medical University, and the Asian Bifurcation Club ("ABC"). The summit was themed on "Definition and therapeutic strategy of complex bifurcation lesions" and covered hot topics such as "Utilization of DK crush for the complex bifurcation" and "Utilization and significance of intra-coronary imaging techniques." The summit aims to build an academic exchange platform for cardiac intervention surgeons regarding the interventional treatment of coronary bifurcation lesions, through reports of the latest clinical trials, case analysis and discussions, operation demonstrations and rebroadcasting, and symposiums in cooperation with EuroPCR. During the summit, MicroPort® received 14 experts from the Europe, the US, Latin America and Asia Pacific, and five of them were participating the CBS for the first time.
In the summit, live operation demonstrations of MicroPort® in-house developed Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") and Firebird2® Rapamycin-Eluting Coronary CoCr Stent System ("Firebird2®") were broadcasted to the attendees. The operations were performed by nine experts in Nanjing First Hospital. Professor Tak W Kwan from the US implanted Firehawk® in some complex bifurcation lesions and all achieved excellent outcome. Firehawk® showed outstanding crossability and support in the treatment of bifurcation lesions. With advanced techniques such as DK crush, Firehawk® performed perfectly in the observation of IVUS, OCT and other high-definition imaging devices, and achieved satisfactory immediate operation effect. Dr. Agostoni from the Netherlands used four Firehawk® stents in a non-live CTO. It was the first time Dr. Agostoni used Firehawk® and he spoke highly of the crossability of the device. Professor S. Tanveer Rab from the US used 38mm Firehawk® long stent – Firehawk® long stent is often the preferred choice of surgeons in treating long and complex lesions. Professor Ramesh Daggubati from the US implanted Firebird2® and passed the lesion in extremely short period of time, which demonstrated Firebird2®'s excellent crossability.
Taking the opportunity of this summit, two Dutch experts Dr. Heyden and Dr. Agostoni visited MicroPort® and said they were impressed by the environment, equipment of its production plant as well as the earnest manner of the plant workers. In particular, Dr. Heyden highly recognized the strict standard of the production process and perfectly clean environment of the MicroPort® plant. During their visit in MicroPort® Self-Experience Center, the two experts showed great interest in MicroPort®'s company culture, especially its management credo "Eyes for Greatness, Hands on Details."
This summit further strengthened and promoted the academic exchange and cooperation between China and other countries, which enabled domestic and international experts of interventional therapy to get a deeper understanding in MicroPort® and its products. As a leading high-end medical device company in China, MicroPort® will continue to stick to innovation in its product R&D, and provide academic exchange platforms for cardiac intervention experts by attending more significant and influential academic events such as CBS.